See more : STORAGE-OH Co.,Ltd. (2997.T) Income Statement Analysis – Financial Results
Complete financial analysis of Canntab Therapeutics Limited (CTABF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Canntab Therapeutics Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Zotefoams plc (ZTF.L) Income Statement Analysis – Financial Results
- Investeringsforeningen Wealth Invest – Timeinvest Sustainable Opportunities AKL (WEITISOP.CO) Income Statement Analysis – Financial Results
- Kyushu Electric Power Company, Incorporated (KYSEY) Income Statement Analysis – Financial Results
- Shanghai Junshi Biosciences Co., Ltd. (SHJBF) Income Statement Analysis – Financial Results
- Yamau Holdings Co., Ltd. (5284.T) Income Statement Analysis – Financial Results
Canntab Therapeutics Limited (CTABF)
About Canntab Therapeutics Limited
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 293.36K | 0.00 | 133.33K | 240.00K | 26.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.16K | 0.00 |
| Cost of Revenue | 1.23M | 546.34K | 0.00 | 96.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -939.01K | -546.34K | 133.33K | 143.61K | 26.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.16K | 0.00 |
| Gross Profit Ratio | -320.09% | 0.00% | 100.00% | 59.84% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 205.03K | 80.36K | 105.75K | 128.14K | 140.73K | 40.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.60M | 2.58M | 2.34M | 2.44M | 2.13M | 1.07M | 173.84K | 178.77K | 312.39K | 346.86K | 366.02K | 49.91K |
| Selling & Marketing | 226.39K | 128.18K | 168.51K | 0.00 | 126.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.83M | 2.70M | 2.34M | 2.44M | 2.26M | 1.07M | 173.84K | 178.77K | 312.39K | 346.86K | 366.02K | 49.91K |
| Other Expenses | 192.91K | -429.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.23M | 3.33M | 2.75M | 2.74M | 2.45M | 1.12M | 173.84K | 178.77K | 587.32K | 1.45M | 1.46M | 100.41K |
| Cost & Expenses | 4.46M | 3.33M | 2.75M | 2.74M | 2.45M | 1.12M | 173.84K | 178.77K | 587.32K | 1.45M | 1.46M | 100.41K |
| Interest Income | 0.00 | 0.00 | 8.46K | 43.19K | 15.01K | 313.00 | 0.00 | 0.00 | 429.00 | 4.51K | 10.16K | 0.00 |
| Interest Expense | 566.67K | 188.72K | 26.58K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 634.72K | 546.34K | 295.62K | 80.61K | 51.48K | 1.62K | -347.68K | -236.00 | -235.27K | 223.75K | 0.00 | 0.00 |
| EBITDA | -2.49M | -3.13M | -2.32M | -2.42M | -2.37M | -1.11M | -173.84K | -179.00K | -872.97K | -1.33M | -1.45M | -100.41K |
| EBITDA Ratio | -848.03% | 0.00% | -1,740.06% | -1,008.82% | -8,894.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,293.36% | 0.00% |
| Operating Income | -4.16M | -3.78M | -2.62M | -2.50M | -2.42M | -1.12M | 173.84K | -178.77K | -637.71K | -1.56M | -1.45M | -100.41K |
| Operating Income Ratio | -1,419.41% | 0.00% | -1,961.77% | -1,042.41% | -9,087.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,293.36% | 0.00% |
| Total Other Income/Expenses | 474.83K | -900.30K | 0.00 | 43.19K | 15.01K | 313.00 | -347.68K | 236.00 | 336.46K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -3.69M | -4.42M | -2.61M | -2.46M | -2.41M | -1.12M | -173.84K | -178.53K | -301.24K | -1.56M | 0.00 | 0.00 |
| Income Before Tax Ratio | -1,257.55% | 0.00% | -1,955.42% | -1,024.41% | -9,031.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 188.72K | 89.32K | -91.25K | 0.00 | -50.90K | -370.50K | 0.00 | -50.81K | -114.13K | 1.45M | 100.41K |
| Net Income | -3.69M | -4.42M | -2.61M | -2.46M | -2.41M | -1.12M | -173.84K | -178.53K | -301.24K | -1.56M | -1.45M | -100.41K |
| Net Income Ratio | -1,257.55% | 0.00% | -1,955.42% | -1,024.41% | -9,031.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,293.36% | 0.00% |
| EPS | -0.10 | -0.13 | -0.10 | -0.10 | -0.11 | -0.07 | -0.75 | -1.18 | -1.53 | -8.30 | -9.38 | -1.65 |
| EPS Diluted | -0.10 | -0.13 | -0.10 | -0.10 | -0.11 | -0.07 | -0.75 | -1.18 | -1.53 | -8.30 | -9.38 | -1.65 |
| Weighted Avg Shares Out | 37.72M | 34.55M | 27.17M | 25.30M | 21.13M | 15.00M | 230.28K | 151.38K | 196.69K | 187.58K | 154.73K | 60.70K |
| Weighted Avg Shares Out (Dil) | 37.72M | 34.55M | 27.17M | 25.30M | 21.13M | 15.00M | 230.28K | 151.38K | 196.69K | 187.58K | 154.73K | 60.70K |
Canntab Therapeutics wins Australian patent related to its proprietary cannabidiol formulations
Canntab Therapeutics Limited (CSE:PILL) (OTCQB:CTABF) (FRA:TBF1) announced Tuesday that the Australian Patent Office has granted the company a patent related to its proprietary cannabidiol formulations. In addition, the company reported it has now received an initial purchase order of $406,200...
Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia
3rd Patent Grant with Australia following the United States and Canada Initial Australian Purchase Order of $406,200 from our Australian partner Cann Global Limited Participation in Australia's Largest Cannabis Research Study TORONTO, March 9, 2021 /PRNewswire/ - Canntab Therapeutics...
Canntab Therapeutics says it has completed its second delivery of two additional SKU's ordered by MediPharm Labs
Canntab Therapeutics Limited (CSE:PILL) (OTCQB:CTABF) (FRA:TBF1) said it has completed its second delivery of two additional SKU's ordered by MediPharm Labs Corp, including 12.5mg CBD caplets (hard tablets in the shape of capsules) and 25mg CBD caplets for approximately $550,000.00. The...
Canntab Engages Independent Trading Group for Market Making Services
Toronto, Ontario--(Newsfile Corp. - February 17, 2021) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announced today that it...
Canntab Grants Options
Toronto, Ontario--(Newsfile Corp. - February 3, 2021) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) (the "Company" or "Canntab") announces that it has granted, in accordance with the Company's stock option plan, an aggregate of 50,000 options to...
Canntab Granted 2nd Patent For Immediate Release Cannabidiol Formulation Tablets
TORONTO, Feb. 1, 2021 /PRNewswire/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is thrilled to announce the Canadian...
Canntab Announces Closing of Convertible Debenture Private Placement
Toronto, Ontario--(Newsfile Corp. - December 31, 2020) - Canntab Therapeutics Limited. (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) ("Canntab" or the "Company"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the closing...
Source: https://incomestatements.info
Category: Stock Reports